Although radionuclides possess unique diagnostic and therapeutic features, they are not able to selectively target tumor sites (with only few exceptions, e.g. 131I can passively accumulate at the tumor tissues, expressing sodium/iodide symporter (NIS) [3–5]), thus, issues related to the radionuclide delivery become an area of a significant interest and growth. Here, SLC5A5 is linked to neoplasm.